News Releases

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses -

- Expanded executive team as Lourie Zak appointed Chief Financial Officer -  - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) --   Genelux Corporation (NASDAQ: GNLX),

WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock

WESTLAKE VILLAGE, Calif. , Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C.

WESTLAKE VILLAGE, Calif. , Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023 .

-  Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private placements in Q2, totaling $65 million raised in the first half of 2023 - - Current cash and cash

WESTLAKE VILLAGE, Calif. , Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in

WESTLAKE VILLAGE, Calif. , July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new members to its leadership team.

Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center , New York , investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density

- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherapy ® (vaccine-enhanced adoptive T cell therapy).